Lung spirometry parameters and diffusion capacity are decreased in patients with Type 2 diabetes

Klein, Oana L.; Kalhan, Ravi; Williams, Mark; Tipping, Matthew D.; Lee, Jung Hwa; Peng, Jie; Smith, Lewis J.

doi:10.1111/j.1464-5491.2011.03394.x

Cited by 43 publications

(40 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…d Missing data were not imputed except for the 1 measure of FVC change, which was imputed using the clinical trial methodology. [18,31,32]. Additionally, patients with IPF and a history of diabetes were shown to have an increased risk of mortality [33].…”

Section: Discussionmentioning

confidence: 99%

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis

et al. 2018

View full text Add to dashboard Cite

Background: Diabetes mellitus is a possible risk factor for the development of idiopathic pulmonary fibrosis (IPF), yet the effect of antidiabetic therapy on the course of IPF is unknown. Objectives: This post hoc analysis assessed the effect of metformin on clinically relevant outcomes in patients with IPF. Methods: For the primary analysis, patients randomized to placebo (n = 624) in 3 phase 3, double-blind, controlled trials of pirfenidone (CAPACITY [NCT00287716 and NCT00287729]; ASCEND [NCT01366209]) were categorized by baseline metformin use. The primary outcome was disease progression (forced vital capacity [FVC] decline ≥10%, 6-min walking distance [6MWD] decline ≥50 m, or death). Other outcomes included mortality, hospitalization, FVC decline (≥10 and ≥5%), and 6MWD decline. Outcomes were also assessed in patients with diabetes and/or hyperglycemia (impaired glucose tolerance [IGT] and diabetes population [IGT-diabetes population]) and all patients included in the 3 studies (intention-to-treat [ITT] population). Results: Overall, 71 (11.4%) patients were metformin users and 553 (88.6%) were nonmetformin users. Baseline data were similar between groups, except for a higher percentage of males (84.5 vs. 73.2%) and a history of diabetes (98.6 vs. 11.6%) in metformin users versus nonmetformin users. The unadjusted 1-year analyses demonstrated no significant differences in disease progression or other outcomes. A higher proportion of metformin users compared with nonmetformin users had a relative FVC decline of ≥5% (63.4 vs. 50.6%, p = 0.043). Results were similar for the IGT-diabetes population and for the ITT population. Multivariable analyses yielded similar results. Conclusions: Metformin has no effect on clinically relevant outcomes in patients with IPF.

show abstract

Section: Discussionmentioning

confidence: 99%

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Some of these studies found that lung dysfunction correlates with DM control, duration, and microvascular complications (1,4,5). …”

Section: Introductionmentioning

confidence: 99%

Hispanics/Latinos With Type 2 Diabetes Have Functional and Symptomatic Pulmonary Impairment Mirroring Kidney Microangiopathy: Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

Klein

Avilés-Santa

Cai³

et al. 2016

Diabetes Care

View full text Add to dashboard Cite

OBJECTIVEType 2 diabetes mellitus (DM) has been associated with lung dysfunction, but this association has not been explored in Hispanics/Latinos. The relation between diabetic nephropathy and lung function and symptoms has not been explored.RESEARCH DESIGN AND METHODSThe Hispanic Community Health Study/Study of Latinos (HCHS/SOL), a large, multicenter, observational study, recruited 16,415 participants aged 18–74 years (14,455 with complete data on variables of interest), between 2008 and 2011 from four U.S. communities through a two-stage area household probability design. Baseline measurements were used for analyses. Forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and dyspnea score were compared between individuals with and without DM, overall, and stratified by albuminuria. The analyses were performed separately for those with and without preexisting lung disease (chronic bronchitis, emphysema, asthma). Linear regression with sampling weights was used for all analyses.RESULTSAmong Hispanics/Latinos without lung disease, those with DM had lower mean FEV1 and FVC values and a higher mean dyspnea score than those without DM (mean [95% CI] FEV1 3.00 [2.96–3.04] vs. 3.10 [3.09–3.11] L, P < 0.01; FVC 3.62 [3.59–3.66] vs. 3.81 [3.79–3.83] L, P < 0.001; dyspnea score 0.60 [0.49–0.71] vs. 0.41 [0.34–0.49], P < 0.001). Hispanics/Latinos with DM and macroalbuminuria showed 10% lower FVC (P < 0.001), 6% lower FEV1 (P < 0.001), and 2.5-fold higher dyspnea score (P = 0.04) than those without DM and with normoalbuminuria. Similar findings but with higher impairment in FVC were found in Hispanics/Latinos with lung disease.CONCLUSIONSHispanics/Latinos with DM have functional and symptomatic pulmonary impairment that mirror kidney microangiopathy. The progression of pulmonary impairment in adults with DM needs to be investigated further.

show abstract

“…Information on medical history was considered valid when it was reported in more than one note in the medical record. Because of the possibility of interaction between smoking, lung disease history, and diabetes mellitus, a condition that has been reported to affect pulmonary function, 27 we tested for possible interaction between spirometric variables and smoking, lung disease, and diabetes.…”

Section: What This Paper Contributes To Our Knowledgementioning

confidence: 99%

Pulmonary Function Testing and Outcomes in Subjects With Heart Failure Listed for Heart Transplantation

Georgiopoulou

Deka

et al. 2015

Respir Care

View full text Add to dashboard Cite

BACKGROUND: Impaired spirometric parameters have been reported in patients with stage C heart failure and portend worse outcomes in these patients. The impact of spirometric parameters on outcomes in patients with stage D heart failure listed for heart transplantation is unknown. METHODS: We collected data on consecutive subjects listed for heart transplantation and examined the association of FEV 1 , FVC, and FEV 1 /FVC with (1) death or left ventricular assist device implantation (primary end point) and (2)

show abstract

Lung spirometry parameters and diffusion capacity are decreased in patients with Type 2 diabetes

Abstract: Patients with diabetes have decreased lung function compared with those without diabetes. Caucasians with diabetes have more global lung function impairment compared with African-Americans and Hispanics.

Cited by 43 publications

References 29 publications

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis

Hispanics/Latinos With Type 2 Diabetes Have Functional and Symptomatic Pulmonary Impairment Mirroring Kidney Microangiopathy: Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

Pulmonary Function Testing and Outcomes in Subjects With Heart Failure Listed for Heart Transplantation

Contact Info

Product

Resources

About